<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Raynaud Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Raynaud Disease</span>
        </nav>

        <header class="page-header">
            <h1>Raynaud Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Complex</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008364" target="_blank">
                        MONDO:0008364
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Vascular Disorder</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Raynaud disease (primary Raynaud phenomenon) is a vasospastic disorder characterized by episodic, excessive vasoconstriction of digital arteries and arterioles triggered by cold exposure or emotional stress. It manifests as triphasic color changes of the fingers and toes (pallor, cyanosis, erythema) reflecting vasospasm, deoxygenation, and reperfusion hyperemia. Primary Raynaud disease occurs without an underlying connective tissue disease and involves primarily functional vascular abnormalities. Secondary Raynaud phenomenon is associated with autoimmune conditions such as systemic sclerosis and involves both functional and structural vascular changes. The pathogenesis involves dysregulated neurovascular control, endothelial dysfunction, alpha-2C adrenoceptor-mediated vasoconstriction amplified by RhoA/ROCK signaling, and impaired nitric oxide-soluble guanylate cyclase-cGMP vasodilatory pathways.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Genes</div>
            </div>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">◆</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Primary Raynaud Phenomenon
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Idiopathic vasospastic episodes without underlying connective tissue disease. Primarily functional vascular abnormalities with symmetric involvement, younger age of onset, and milder course. Digital tissue damage is uncommon.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In primary RP, the vascular abnormalities are primarily functional."</div>
                
                
                <div class="evidence-explanation">Distinguishes primary RP as functional versus structural in secondary RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Secondary Raynaud Phenomenon
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Raynaud phenomenon occurring in the context of an underlying disease, most commonly systemic sclerosis, systemic lupus erythematosus, or mixed connective tissue disease. Associated with both functional and structural vascular changes and higher risk of digital ulceration and tissue loss.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"in secondary RP, both functional and structural components occur in blood vessels. This explains why digital tissue damage frequently occurs in secondary RP but not primary RP."</div>
                
                
                <div class="evidence-explanation">Structural vascular changes explain complications in secondary RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction</div>
                
                <div class="item-desc">Cold triggers alpha-2C adrenoceptor (ADRA2C) activation in microvascular smooth muscle cells, mediating local cooling-induced vasoconstriction of digital arteries and arterioles. Alpha-2C-AR is the sole mediator of cold-induced vasoconstriction in the peripheral vasculature.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Vascular Smooth Muscle Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000359" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Vasoconstriction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042310" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Cellular Response to Cold
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070417" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Digital Artery
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0004552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25770637" target="_blank">PMID:25770637</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors"</div>
                
                
                <div class="evidence-explanation">Alpha-2 adrenoceptor hyperactivity drives the exaggerated smooth muscle contraction.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40506673" target="_blank">PMID:40506673</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"estrogen plays a fundamental role in potentiating the expression and function of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced vasoconstriction"</div>
                
                
                <div class="evidence-explanation">Identifies alpha-2C-AR as the sole mediator of cold-induced vasospasm.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">RhoA/ROCK Potentiation of Vasospasm</div>
                
                <div class="item-desc">RhoA/ROCK signaling potentiates alpha-2C adrenoceptor-mediated vasoconstriction and reactive oxygen species generation in vascular smooth muscle cells, amplifying the vasospastic response to cold.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Vascular Smooth Muscle Contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014829" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon (RP) is a condition characterized by episodic, excessive vasoconstriction in the fingers and toes, triggered by cold or stress."</div>
                
                
                <div class="evidence-explanation">Establishes the core vasospastic mechanism that RhoA/ROCK potentiates.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Estrogen Potentiation of Alpha-2C-AR</div>
                
                <div class="item-desc">Estrogen potentiates alpha-2C adrenoceptor expression and function, contributing to the significantly higher incidence of Raynaud phenomenon in premenopausal females compared to age-matched males.
</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40506673" target="_blank">PMID:40506673</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon incidence is significantly higher in premenopausal females compared to age-matched males, highlighting a role of the female hormone, estrogen, in Raynaud&#39;s phenomenon pathogenesis."</div>
                
                
                <div class="evidence-explanation">Estrogen potentiates alpha-2C-AR, explaining sex-based differences in RP incidence.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Endothelial Dysfunction</div>
                
                <div class="item-desc">Impaired endothelium-dependent vasodilation with reduced nitric oxide (NO) and prostacyclin bioavailability and increased production of endothelin-1 (ET-1). The imbalance between vasoconstrictors and vasodilators favors persistent vasoconstriction, platelet activation, and intimal proliferation. In secondary RP associated with systemic sclerosis, endothelial damage leads to defective angiogenesis, endothelial-to-mesenchymal transition, and progressive capillary loss.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Endothelial Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Vasodilation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042311" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Nitric Oxide Biosynthesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006809" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/ijms241814385" target="_blank">DOI:10.3390/ijms241814385</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Endothelial damage and activation occur early, possibly triggered by various infectious agents and autoantibodies. Endothelial dysfunction, along with defects in endothelial progenitor cells, leads to defective angiogenesis and vasculogenesis."</div>
                
                
                <div class="evidence-explanation">Endothelial dysfunction is an early event driving vascular pathology.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.3390/biomedicines12061331" target="_blank">DOI:10.3390/biomedicines12061331</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"once damaged, endothelial cells can be dysfunctionally activated, thus becoming unable to undergo angiogenesis and promoting perivascular inflammation. They can also undergo apoptosis, transdifferentiate into profibrotic myofibroblasts"</div>
                
                
                <div class="evidence-explanation">Describes mechanisms of endothelial dysfunction including EndoMT and failed angiogenesis in SSc-associated RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Sympathetic Nervous System Dysregulation</div>
                
                <div class="item-desc">Increased sympathetic adrenergic control of digital resistance vessels contributes to exaggerated cold-induced vasoconstriction. The pathogenesis involves a complex interaction between the vascular wall, nerves, hormones, and humoral factors disrupting the balance between vasoconstriction and vasodilation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Sympathetic Neuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0011103" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Temperature Homeostasis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001659" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Manual Digit
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002389" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The pathogenesis of RP involves a complex interaction between the vascular wall, nerves, hormones, and humoral factors, disrupting the balance between vasoconstriction and vasodilation."</div>
                
                
                <div class="evidence-explanation">Neurovascular dysregulation as a central mechanism.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Intravascular and Platelet Abnormalities</div>
                
                <div class="item-desc">Platelet activation and release of thromboxane A2 and serotonin contribute to vasospasm. Altered coagulation and fibrinolysis pathways and increased blood viscosity further impair microvascular flow during episodes. Gene ontology analysis identifies enrichment in negative regulation of fibrinolysis and complement/coagulation cascades among RP-associated genes.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Platelet
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000233" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Platelet Activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030168" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1515/tjb-2023-0197" target="_blank">DOI:10.1515/tjb-2023-0197</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A significant enrichment by gene ontology enrichment analysis was detected in a subset of genes involved in biological processes including cellular response to luteinizing hormone stimulus, negative regulation of fibrinolysis, negative regulation of smooth muscle cell apoptotic process,..."</div>
                
                
                <div class="evidence-explanation">GO analysis of RP-associated genes shows enrichment in coagulation/fibrinolysis pathways relevant to intravascular abnormalities.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://bioregistry.io/DOI:10.1515/tjb-2023-0197" target="_blank">DOI:10.1515/tjb-2023-0197</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Through the use of KEGG pathways, we were able to identify many molecular processes that contribute to RP, including the AGE-RAGE signaling pathway in diabetic complications, complement and coagulation cascades, fluid shear stress, atherosclerosis."</div>
                
                
                <div class="evidence-explanation">KEGG analysis confirms complement/coagulation cascade involvement in RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oxidative Stress and Ischemia-Reperfusion Injury</div>
                
                <div class="item-desc">Recurrent vasospastic episodes cause ischemia-reperfusion injury with generation of reactive oxygen species (ROS) and endothelial damage. ROS-dependent signaling also regulates alpha-2C-AR expression and translocation in vascular smooth muscle cells, creating a feed-forward loop of vascular dysfunction.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Response to Oxidative Stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006979" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24418302" target="_blank">PMID:24418302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"recent advances in our understanding of the pathophysiology have highlighted novel potential therapeutic targets"</div>
                
                
                <div class="evidence-explanation">Prete et al. review discusses pathogenic mechanisms including oxidative stress in RP pathophysiology.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">⬡</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Alpha_2C_Adrenoceptor_Cold_Induced_Vasoconstriction[&#34;Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction&#34;]
    RhoA_ROCK_Potentiation_of_Vasospasm[&#34;RhoA/ROCK Potentiation of Vasospasm&#34;]

    Alpha_2C_Adrenoceptor_Cold_Induced_Vasoconstriction --&gt; RhoA_ROCK_Potentiation_of_Vasospasm

    style Alpha_2C_Adrenoceptor_Cold_Induced_Vasoconstriction fill:#dbeafe
    style RhoA_ROCK_Potentiation_of_Vasospasm fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">5</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Nervous System<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Raynaud Phenomenon
                        
                        <span class="phenotype-freq">OBLIGATE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0030880" target="_blank">
                                Raynaud phenomenon
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0030880)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25770637" target="_blank">PMID:25770637</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud syndrome (RS) was first described by the French physician Maurice Raynaud in 1862 with the characteristic tricolor change featuring pallor (ischemic phase), cyanosis (deoxygenation phase), and erythema (reperfusion phase) induced by cold or stress."</div>
                
                
                <div class="evidence-explanation">Classic triphasic color change as the hallmark clinical feature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24418302" target="_blank">PMID:24418302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon (RP) is a well defined clinical syndrome characterized by recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress."</div>
                
                
                <div class="evidence-explanation">Defines RP as a clinical syndrome of recurrent digital vasospasm.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Digital Pain and Paresthesia
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003401" target="_blank">
                                Paresthesia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003401)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29237099" target="_blank">PMID:29237099</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon is a vasospastic disease characterized by digital pallor, cyanosis, and extremity pain."</div>
                
                
                <div class="evidence-explanation">Pain is a core characteristic feature of Raynaud phenomenon.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Acrocyanosis
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001063" target="_blank">
                                Acrocyanosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001063)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pallor indicates reduced blood flow due to oxygen deprivation, while erythema appears as reperfusion."</div>
                
                
                <div class="evidence-explanation">Describes the color change phases including cyanosis between pallor and erythema.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Digital Ulceration
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0031917" target="_blank">
                                Digital ulcer
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0031917)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"digital tissue damage frequently occurs in secondary RP but not primary RP"</div>
                
                
                <div class="evidence-explanation">Digital ulceration is characteristic of secondary rather than primary RP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24418302" target="_blank">PMID:24418302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"sRP can evolve and be complicated by acral digital ulcers and gangrene, which may require surgical treatment"</div>
                
                
                <div class="evidence-explanation">Secondary RP can progress to digital ulcers and gangrene.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Digital Ischemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0033402" target="_blank">
                                Digital ischemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0033402)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pallor indicates reduced blood flow due to oxygen deprivation"</div>
                
                
                <div class="evidence-explanation">Digital pallor reflects ischemia from vasospasm-induced blood flow reduction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Calcium Channel Blockers
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        nifedipine
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_7565" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        amlodipine
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_2668" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are first-line pharmacotherapy. They reduce frequency and severity of vasospastic attacks by inhibiting calcium influx into vascular smooth muscle cells.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Dihydropyridine calcium channel blockers (CCBs), such as nifedipine, are commonly used for vasodilation."</div>
                
                
                <div class="evidence-explanation">CCBs are established first-line pharmacotherapy for RP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29237099" target="_blank">PMID:29237099</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"CCBs (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud&#39;s phenomenon."</div>
                
                
                <div class="evidence-explanation">Cochrane systematic review of 38 RCTs demonstrating CCBs reduce attack frequency and severity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cold Avoidance and Protective Measures
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Behavioral modification including wearing warm gloves, avoiding cold exposure, and using hand warmers. First-line non-pharmacological management for all patients with Raynaud phenomenon.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25770637" target="_blank">PMID:25770637</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Most patients with RS can be managed conservatively, with avoidance of cold exposure or hand warming."</div>
                
                
                <div class="evidence-explanation">Conservative management with cold avoidance is first-line for most patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Phosphodiesterase-5 Inhibitors
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        sildenafil
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_9139" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                    <span class="tag tag-treatment">
                        tadalafil
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_71940" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Sildenafil and tadalafil improve digital blood flow by inhibiting PDE5, increasing cGMP levels, and enhancing nitric oxide-mediated vasodilation. Used as second-line therapy for refractory cases or when CCBs are insufficient.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage."</div>
                
                
                <div class="evidence-explanation">PDE5 inhibitors are second-line options for refractory RP.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28281457" target="_blank">PMID:28281457</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Sildenafil improved digital blood flow and RP symptoms in SSc patients after 8 weeks of treatment, and might be a good therapeutic option for secondary RP."</div>
                
                
                <div class="evidence-explanation">RCT demonstrating sildenafil improves microvascular blood flow in SSc-associated RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Prostacyclin Analogues
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        iloprost
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_63916" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Intravenous iloprost is used for severe Raynaud phenomenon with digital ischemia or ulceration. Provides potent vasodilation and antiplatelet effects.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative options for patients who do not respond to CCBs or have ischemic tissue damage."</div>
                
                
                <div class="evidence-explanation">Prostacyclin analogs are alternative options for severe/refractory RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Endothelin Receptor Antagonists
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-meta">
                    <strong style="font-size: 0.8rem; color: #5b21b6;">Drug:</strong>
                    
                    <span class="tag tag-treatment">
                        bosentan
                        
                        <a href="http://purl.obolibrary.org/obo/CHEBI_51450" target="_blank" style="color: inherit; margin-left: 4px;">↗</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Bosentan blocks endothelin-1 receptor signaling and has shown effectiveness in treating and preventing digital ulcers, especially in patients with systemic sclerosis-associated Raynaud phenomenon with multiple ulcers.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Bosentan, an endothelin-1 receptor antagonist, has shown effectiveness in treating and preventing digital ulcers, especially in patients with multiple ulcers."</div>
                
                
                <div class="evidence-explanation">Bosentan is effective for digital ulcer prevention in SSc-associated RP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Sympathectomy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Surgical sympathectomy can be used for severe, refractory Raynaud phenomenon to reduce sympathetic vasoconstriction. Long-term effectiveness is uncertain.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39040029" target="_blank">PMID:39040029</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"sympathectomy surgery can be used to control RP symptoms. However, botulinum toxin injections require repeated administration, and sympathectomy&#39;s long-term effectiveness is uncertain."</div>
                
                
                <div class="evidence-explanation">Sympathectomy is an option for severe cases but has uncertain long-term efficacy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Cold Exposure</div>
                
                
                <div class="item-desc">Cold ambient temperature or direct contact with cold objects is the primary trigger for vasospastic episodes. Cold triggers alpha-2C adrenoceptor-mediated vasoconstriction in digital smooth muscle cells.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40506673" target="_blank">PMID:40506673</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon is a peripheral vascular disorder characterized by exaggerated vasoconstrictive response to certain stimuli, most typically cold exposure and emotional stress."</div>
                
                
                <div class="evidence-explanation">Cold exposure is the primary trigger for RP attacks.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40506673" target="_blank">PMID:40506673</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"estrogen plays a fundamental role in potentiating the expression and function of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced vasoconstriction"</div>
                
                
                <div class="evidence-explanation">Cold exposure activates alpha-2C-AR-mediated vasoconstriction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Emotional Stress</div>
                
                
                <div class="item-desc">Psychological stress and emotional disturbance can trigger vasospastic episodes through sympathetic nervous system activation, independent of cold exposure.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24418302" target="_blank">PMID:24418302</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"recurrent episodes of digital vasospasm triggered by exposure to physical/chemical or emotional stress"</div>
                
                
                <div class="evidence-explanation">Emotional stress is a recognized trigger alongside physical stimuli.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Raynaud Disease
category: Complex
parents:
- Vascular Disorder
disease_term:
  preferred_term: Raynaud disease
  term:
    id: MONDO:0008364
    label: Raynaud disease
synonyms:
- Raynaud Phenomenon
- Raynaud Syndrome
- Primary Raynaud Phenomenon
description: &gt;
  Raynaud disease (primary Raynaud phenomenon) is a vasospastic disorder characterized
  by episodic, excessive vasoconstriction of digital arteries and arterioles triggered
  by cold exposure or emotional stress. It manifests as triphasic color changes of the
  fingers and toes (pallor, cyanosis, erythema) reflecting vasospasm, deoxygenation,
  and reperfusion hyperemia. Primary Raynaud disease occurs without an underlying
  connective tissue disease and involves primarily functional vascular abnormalities.
  Secondary Raynaud phenomenon is associated with autoimmune conditions such as
  systemic sclerosis and involves both functional and structural vascular changes.
  The pathogenesis involves dysregulated neurovascular control, endothelial dysfunction,
  alpha-2C adrenoceptor-mediated vasoconstriction amplified by RhoA/ROCK signaling,
  and impaired nitric oxide-soluble guanylate cyclase-cGMP vasodilatory pathways.
prevalence:
- population: General
  percentage: 3.0
  notes: Estimated prevalence 3-5% in the general population, with higher prevalence
    in women than men.
  evidence:
  - reference: PMID:25770637
    supports: SUPPORT
    snippet: &#34;The estimated prevalence in the general population is 3%-5%, with a higher
      prevalence in women than in men.&#34;
    explanation: General population prevalence estimate from vascular surgery review.
has_subtypes:
- name: Primary Raynaud Phenomenon
  description: &gt;
    Idiopathic vasospastic episodes without underlying connective tissue disease.
    Primarily functional vascular abnormalities with symmetric involvement, younger
    age of onset, and milder course. Digital tissue damage is uncommon.
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;In primary RP, the vascular abnormalities are primarily functional.&#34;
    explanation: Distinguishes primary RP as functional versus structural in secondary RP.
- name: Secondary Raynaud Phenomenon
  description: &gt;
    Raynaud phenomenon occurring in the context of an underlying disease, most commonly
    systemic sclerosis, systemic lupus erythematosus, or mixed connective tissue disease.
    Associated with both functional and structural vascular changes and higher risk of
    digital ulceration and tissue loss.
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;in secondary RP, both functional and structural components occur in blood
      vessels. This explains why digital tissue damage frequently occurs in secondary
      RP but not primary RP.&#34;
    explanation: Structural vascular changes explain complications in secondary RP.
pathophysiology:
- name: Alpha-2C Adrenoceptor Cold-Induced Vasoconstriction
  description: &gt;
    Cold triggers alpha-2C adrenoceptor (ADRA2C) activation in microvascular smooth
    muscle cells, mediating local cooling-induced vasoconstriction of digital arteries
    and arterioles. Alpha-2C-AR is the sole mediator of cold-induced vasoconstriction
    in the peripheral vasculature.
  gene:
    preferred_term: ADRA2C
    term:
      id: hgnc:283
      label: ADRA2C
  cell_types:
  - preferred_term: Vascular Smooth Muscle Cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  biological_processes:
  - preferred_term: Vasoconstriction
    term:
      id: GO:0042310
      label: vasoconstriction
  - preferred_term: Cellular Response to Cold
    term:
      id: GO:0070417
      label: cellular response to cold
  locations:
  - preferred_term: Digital Artery
    term:
      id: UBERON:0004552
      label: digital artery
  downstream:
  - target: RhoA/ROCK Potentiation of Vasospasm
    description: Alpha-2C-AR activation is potentiated by RhoA/ROCK signaling.
  evidence:
  - reference: PMID:25770637
    supports: SUPPORT
    snippet: &#34;alterations in activity of the peripheral adrenoceptor have been implicated,
      specifically an enhanced smooth muscle contraction due to overexpression or
      hyperactivity of postsynaptic alpha 2 receptors&#34;
    explanation: Alpha-2 adrenoceptor hyperactivity drives the exaggerated smooth muscle
      contraction.
  - reference: PMID:40506673
    supports: SUPPORT
    snippet: &#34;estrogen plays a fundamental role in potentiating the expression and function
      of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced
      vasoconstriction&#34;
    explanation: Identifies alpha-2C-AR as the sole mediator of cold-induced vasospasm.
- name: RhoA/ROCK Potentiation of Vasospasm
  description: &gt;
    RhoA/ROCK signaling potentiates alpha-2C adrenoceptor-mediated vasoconstriction
    and reactive oxygen species generation in vascular smooth muscle cells, amplifying
    the vasospastic response to cold.
  biological_processes:
  - preferred_term: Vascular Smooth Muscle Contraction
    term:
      id: GO:0014829
      label: vascular smooth muscle contraction
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon (RP) is a condition characterized by episodic, excessive
      vasoconstriction in the fingers and toes, triggered by cold or stress.&#34;
    explanation: Establishes the core vasospastic mechanism that RhoA/ROCK potentiates.
- name: Estrogen Potentiation of Alpha-2C-AR
  description: &gt;
    Estrogen potentiates alpha-2C adrenoceptor expression and function, contributing
    to the significantly higher incidence of Raynaud phenomenon in premenopausal
    females compared to age-matched males.
  chemical_entities:
  - preferred_term: estrogen
    term:
      id: CHEBI:50114
      label: estrogen
  evidence:
  - reference: PMID:40506673
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon incidence is significantly higher in premenopausal
      females compared to age-matched males, highlighting a role of the female hormone,
      estrogen, in Raynaud&#39;s phenomenon pathogenesis.&#34;
    explanation: Estrogen potentiates alpha-2C-AR, explaining sex-based differences
      in RP incidence.
- name: Endothelial Dysfunction
  description: &gt;
    Impaired endothelium-dependent vasodilation with reduced nitric oxide (NO) and
    prostacyclin bioavailability and increased production of endothelin-1 (ET-1).
    The imbalance between vasoconstrictors and vasodilators favors persistent
    vasoconstriction, platelet activation, and intimal proliferation. In secondary RP
    associated with systemic sclerosis, endothelial damage leads to defective
    angiogenesis, endothelial-to-mesenchymal transition, and progressive capillary loss.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Vasodilation
    term:
      id: GO:0042311
      label: vasodilation
  - preferred_term: Nitric Oxide Biosynthesis
    term:
      id: GO:0006809
      label: nitric oxide biosynthetic process
  evidence:
  - reference: DOI:10.3390/ijms241814385
    supports: SUPPORT
    snippet: &#34;Endothelial damage and activation occur early, possibly triggered by
      various infectious agents and autoantibodies. Endothelial dysfunction, along
      with defects in endothelial progenitor cells, leads to defective angiogenesis
      and vasculogenesis.&#34;
    explanation: Endothelial dysfunction is an early event driving vascular pathology.
  - reference: DOI:10.3390/biomedicines12061331
    supports: SUPPORT
    snippet: &#34;once damaged, endothelial cells can be dysfunctionally activated, thus
      becoming unable to undergo angiogenesis and promoting perivascular inflammation.
      They can also undergo apoptosis, transdifferentiate into profibrotic myofibroblasts&#34;
    explanation: Describes mechanisms of endothelial dysfunction including EndoMT and
      failed angiogenesis in SSc-associated RP.
- name: Sympathetic Nervous System Dysregulation
  description: &gt;
    Increased sympathetic adrenergic control of digital resistance vessels contributes
    to exaggerated cold-induced vasoconstriction. The pathogenesis involves a complex
    interaction between the vascular wall, nerves, hormones, and humoral factors
    disrupting the balance between vasoconstriction and vasodilation.
  cell_types:
  - preferred_term: Sympathetic Neuron
    term:
      id: CL:0011103
      label: sympathetic neuron
  biological_processes:
  - preferred_term: Temperature Homeostasis
    term:
      id: GO:0001659
      label: temperature homeostasis
  locations:
  - preferred_term: Manual Digit
    term:
      id: UBERON:0002389
      label: manual digit
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;The pathogenesis of RP involves a complex interaction between the vascular
      wall, nerves, hormones, and humoral factors, disrupting the balance between
      vasoconstriction and vasodilation.&#34;
    explanation: Neurovascular dysregulation as a central mechanism.
- name: Intravascular and Platelet Abnormalities
  description: &gt;
    Platelet activation and release of thromboxane A2 and serotonin contribute to
    vasospasm. Altered coagulation and fibrinolysis pathways and increased blood
    viscosity further impair microvascular flow during episodes. Gene ontology analysis
    identifies enrichment in negative regulation of fibrinolysis and complement/coagulation
    cascades among RP-associated genes.
  cell_types:
  - preferred_term: Platelet
    term:
      id: CL:0000233
      label: platelet
  biological_processes:
  - preferred_term: Platelet Activation
    term:
      id: GO:0030168
      label: platelet activation
  evidence:
  - reference: DOI:10.1515/tjb-2023-0197
    supports: SUPPORT
    snippet: &#34;A significant enrichment by gene ontology enrichment analysis was detected
      in a subset of genes involved in biological processes including cellular response
      to luteinizing hormone stimulus, negative regulation of fibrinolysis, negative
      regulation of smooth muscle cell apoptotic process, plasminogen activation&#34;
    explanation: GO analysis of RP-associated genes shows enrichment in coagulation/fibrinolysis
      pathways relevant to intravascular abnormalities.
  - reference: DOI:10.1515/tjb-2023-0197
    supports: SUPPORT
    snippet: &#34;Through the use of KEGG pathways, we were able to identify many molecular
      processes that contribute to RP, including the AGE-RAGE signaling pathway in
      diabetic complications, complement and coagulation cascades, fluid shear stress,
      atherosclerosis.&#34;
    explanation: KEGG analysis confirms complement/coagulation cascade involvement in RP.
- name: Oxidative Stress and Ischemia-Reperfusion Injury
  description: &gt;
    Recurrent vasospastic episodes cause ischemia-reperfusion injury with generation
    of reactive oxygen species (ROS) and endothelial damage. ROS-dependent signaling
    also regulates alpha-2C-AR expression and translocation in vascular smooth muscle
    cells, creating a feed-forward loop of vascular dysfunction.
  biological_processes:
  - preferred_term: Response to Oxidative Stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:24418302
    supports: SUPPORT
    snippet: &#34;recent advances in our understanding of the pathophysiology have highlighted
      novel potential therapeutic targets&#34;
    explanation: Prete et al. review discusses pathogenic mechanisms including oxidative
      stress in RP pathophysiology.
phenotypes:
- category: Vascular
  name: Raynaud Phenomenon
  frequency: OBLIGATE
  diagnostic: true
  description: &gt;
    Episodic vasospasm of digital arteries triggered by cold or stress, producing the
    characteristic triphasic color change: pallor (ischemia), cyanosis (deoxygenation),
    and erythema (reperfusion). This is the defining clinical feature.
  phenotype_term:
    preferred_term: Raynaud phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
  evidence:
  - reference: PMID:25770637
    supports: SUPPORT
    snippet: &#34;Raynaud syndrome (RS) was first described by the French physician Maurice
      Raynaud in 1862 with the characteristic tricolor change featuring pallor (ischemic
      phase), cyanosis (deoxygenation phase), and erythema (reperfusion phase) induced
      by cold or stress.&#34;
    explanation: Classic triphasic color change as the hallmark clinical feature.
  - reference: PMID:24418302
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon (RP) is a well defined clinical syndrome characterized
      by recurrent episodes of digital vasospasm triggered by exposure to physical/chemical
      or emotional stress.&#34;
    explanation: Defines RP as a clinical syndrome of recurrent digital vasospasm.
- category: Vascular
  name: Acrocyanosis
  frequency: VERY_FREQUENT
  description: &gt;
    Blue discoloration of affected digits following the ischemic phase, reflecting
    deoxygenation of static venous blood. Represents the second phase of the triphasic
    color change.
  phenotype_term:
    preferred_term: Acrocyanosis
    term:
      id: HP:0001063
      label: Acrocyanosis
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Pallor indicates reduced blood flow due to oxygen deprivation, while
      erythema appears as reperfusion.&#34;
    explanation: Describes the color change phases including cyanosis between pallor
      and erythema.
- category: Pain
  name: Digital Pain and Paresthesia
  frequency: VERY_FREQUENT
  description: &gt;
    Pain, numbness, and tingling in affected digits during and after vasospastic episodes.
    Ischemic pain from vasospasm and neurogenic sensitization are major symptomatic burdens.
  phenotype_term:
    preferred_term: Paresthesia
    term:
      id: HP:0003401
      label: Paresthesia
  evidence:
  - reference: PMID:29237099
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon is a vasospastic disease characterized by digital
      pallor, cyanosis, and extremity pain.&#34;
    explanation: Pain is a core characteristic feature of Raynaud phenomenon.
- category: Dermatological
  name: Digital Ulceration
  frequency: VERY_RARE
  description: &gt;
    Ischemic ulcers at fingertips resulting from recurrent severe ischemia, endothelial
    damage, and failed angiogenesis. Occurs predominantly in secondary Raynaud phenomenon
    associated with systemic sclerosis. Rare in primary Raynaud disease.
  phenotype_term:
    preferred_term: Digital ulcer
    term:
      id: HP:0031917
      label: Digital ulcer
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;digital tissue damage frequently occurs in secondary RP but not primary RP&#34;
    explanation: Digital ulceration is characteristic of secondary rather than primary RP.
  - reference: PMID:24418302
    supports: SUPPORT
    snippet: &#34;sRP can evolve and be complicated by acral digital ulcers and gangrene,
      which may require surgical treatment&#34;
    explanation: Secondary RP can progress to digital ulcers and gangrene.
- category: Vascular
  name: Digital Ischemia
  frequency: FREQUENT
  description: &gt;
    Reduced blood flow to digits during vasospastic episodes causing tissue hypoxia.
    In severe or secondary disease, sustained ischemia may lead to tissue necrosis.
  phenotype_term:
    preferred_term: Digital ischemia
    term:
      id: HP:0033402
      label: Digital ischemia
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Pallor indicates reduced blood flow due to oxygen deprivation&#34;
    explanation: Digital pallor reflects ischemia from vasospasm-induced blood flow reduction.
environmental:
- name: Cold Exposure
  description: &gt;
    Cold ambient temperature or direct contact with cold objects is the primary trigger
    for vasospastic episodes. Cold triggers alpha-2C adrenoceptor-mediated vasoconstriction
    in digital smooth muscle cells.
  exposure_term:
    preferred_term: exposure to decreased temperature
    term:
      id: ECTO:0001057
      label: exposure to decreased temperature
  evidence:
  - reference: PMID:40506673
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon is a peripheral vascular disorder characterized by
      exaggerated vasoconstrictive response to certain stimuli, most typically cold
      exposure and emotional stress.&#34;
    explanation: Cold exposure is the primary trigger for RP attacks.
  - reference: PMID:40506673
    supports: SUPPORT
    snippet: &#34;estrogen plays a fundamental role in potentiating the expression and function
      of α2C adrenoceptor (α2C-AR), the sole mediator of local cooling-induced
      vasoconstriction&#34;
    explanation: Cold exposure activates alpha-2C-AR-mediated vasoconstriction.
- name: Emotional Stress
  description: &gt;
    Psychological stress and emotional disturbance can trigger vasospastic episodes
    through sympathetic nervous system activation, independent of cold exposure.
  evidence:
  - reference: PMID:24418302
    supports: SUPPORT
    snippet: &#34;recurrent episodes of digital vasospasm triggered by exposure to
      physical/chemical or emotional stress&#34;
    explanation: Emotional stress is a recognized trigger alongside physical stimuli.
treatments:
- name: Calcium Channel Blockers
  description: &gt;
    Dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are
    first-line pharmacotherapy. They reduce frequency and severity of vasospastic
    attacks by inhibiting calcium influx into vascular smooth muscle cells.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: nifedipine
      term:
        id: CHEBI:7565
        label: nifedipine
    - preferred_term: amlodipine
      term:
        id: CHEBI:2668
        label: amlodipine
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Dihydropyridine calcium channel blockers (CCBs), such as nifedipine, are
      commonly used for vasodilation.&#34;
    explanation: CCBs are established first-line pharmacotherapy for RP.
  - reference: PMID:29237099
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;CCBs (especially the dihydropyridine class) may be useful in reducing the
      frequency, duration, severity of attacks, pain and disability associated with
      Raynaud&#39;s phenomenon.&#34;
    explanation: Cochrane systematic review of 38 RCTs demonstrating CCBs reduce attack
      frequency and severity.
- name: Cold Avoidance and Protective Measures
  description: &gt;
    Behavioral modification including wearing warm gloves, avoiding cold exposure,
    and using hand warmers. First-line non-pharmacological management for all patients
    with Raynaud phenomenon.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:25770637
    supports: SUPPORT
    snippet: &#34;Most patients with RS can be managed conservatively, with avoidance of cold
      exposure or hand warming.&#34;
    explanation: Conservative management with cold avoidance is first-line for most patients.
- name: Phosphodiesterase-5 Inhibitors
  description: &gt;
    Sildenafil and tadalafil improve digital blood flow by inhibiting PDE5, increasing
    cGMP levels, and enhancing nitric oxide-mediated vasodilation. Used as second-line
    therapy for refractory cases or when CCBs are insufficient.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: sildenafil
      term:
        id: CHEBI:9139
        label: sildenafil
    - preferred_term: tadalafil
      term:
        id: CHEBI:71940
        label: tadalafil
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative
      options for patients who do not respond to CCBs or have ischemic tissue damage.&#34;
    explanation: PDE5 inhibitors are second-line options for refractory RP.
  - reference: PMID:28281457
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &#34;Sildenafil improved digital blood flow and RP symptoms in SSc patients
      after 8 weeks of treatment, and might be a good therapeutic option for secondary RP.&#34;
    explanation: RCT demonstrating sildenafil improves microvascular blood flow in
      SSc-associated RP.
- name: Prostacyclin Analogues
  description: &gt;
    Intravenous iloprost is used for severe Raynaud phenomenon with digital ischemia
    or ulceration. Provides potent vasodilation and antiplatelet effects.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: iloprost
      term:
        id: CHEBI:63916
        label: iloprost
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Phosphodiesterase-5 inhibitors and prostaglandin analogs are alternative
      options for patients who do not respond to CCBs or have ischemic tissue damage.&#34;
    explanation: Prostacyclin analogs are alternative options for severe/refractory RP.
- name: Endothelin Receptor Antagonists
  description: &gt;
    Bosentan blocks endothelin-1 receptor signaling and has shown effectiveness in
    treating and preventing digital ulcers, especially in patients with systemic
    sclerosis-associated Raynaud phenomenon with multiple ulcers.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: bosentan
      term:
        id: CHEBI:51450
        label: bosentan
  evidence:
  - reference: PMID:39040029
    supports: SUPPORT
    snippet: &#34;Bosentan, an endothelin-1 receptor antagonist, has shown effectiveness in
      treating and preventing digital ulcers, especially in patients with multiple
      ulcers.&#34;
    explanation: Bosentan is effective for digital ulcer prevention in SSc-associated RP.
- name: Sympathectomy
  description: &gt;
    Surgical sympathectomy can be used for severe, refractory Raynaud phenomenon
    to reduce sympathetic vasoconstriction. Long-term effectiveness is uncertain.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:39040029
    supports: PARTIAL
    snippet: &#34;sympathectomy surgery can be used to control RP symptoms. However, botulinum
      toxin injections require repeated administration, and sympathectomy&#39;s long-term
      effectiveness is uncertain.&#34;
    explanation: Sympathectomy is an option for severe cases but has uncertain long-term
      efficacy.
notes: &gt;
  Raynaud phenomenon was first described by the French physician Maurice Raynaud in
  1862. The condition affects approximately 3-5% of the general population with a
  higher prevalence in women. Primary RP is a benign condition with functional vascular
  abnormalities, while secondary RP (associated with systemic sclerosis, SLE, and
  other connective tissue diseases) involves structural vascular changes and risk of
  digital ulcers. Diagnosis is primarily clinical, with nailfold capillaroscopy serving
  as the gold standard for distinguishing primary from secondary RP. Genetic and
  hormonal factors (particularly estrogen) are likely contributors, and GWAS-identified
  genes are enriched in vascular damage and fibrosis pathways.
datasets:
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Raynaud_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>